These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15375314)

  • 21. Antisense anticancer oligonucleotide therapeutics.
    Wang H; Prasad G; Buolamwini JK; Zhang R
    Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?
    Stewart A
    Mol Med Today; 1997 Aug; 3(8):324. PubMed ID: 9269683
    [No Abstract]   [Full Text] [Related]  

  • 23. Chemosensitization by antisense oligonucleotides targeting MDM2.
    Bianco R; Ciardiello F; Tortora G
    Curr Cancer Drug Targets; 2005 Feb; 5(1):51-6. PubMed ID: 15720189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Suppression of expression of bcl-2 and bcl-xL genes using antisense oligonucleotides: a new approach to cancer therapy].
    Lebedeva IV; Staĭn SA
    Mol Biol (Mosk); 2000; 34(6):1025-38. PubMed ID: 11186002
    [No Abstract]   [Full Text] [Related]  

  • 25. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RI alpha subunit: p53-independent mechanism of action.
    Srivastava RK; Srivastava AR; Seth P; Agrawal S; Cho-Chung YS
    Mol Cell Biochem; 1999 May; 195(1-2):25-36. PubMed ID: 10395066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
    Kim R; Emi M; Matsuura K; Tanabe K
    Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors.
    Altmann KH; Fabbro D; Dean NM; Geiger T; Monia BP; Müller M; Nicklin P
    Biochem Soc Trans; 1996 Aug; 24(3):630-7. PubMed ID: 8878817
    [No Abstract]   [Full Text] [Related]  

  • 30. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
    Roychowdhury D; Lahn M
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer.
    Gleave M; Nelson C; Chi K
    Curr Drug Targets; 2003 Apr; 4(3):209-21. PubMed ID: 12643471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bcl-2 family members as molecular targets in cancer therapy.
    Marzo I; Naval J
    Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antisense oligonucleotides and the rational design of new antitumor drugs.
    Prieto J; Hernández-Alcoceba R
    Rev Esp Enferm Dig; 2005 Jul; 97(7):467-71. PubMed ID: 16262525
    [No Abstract]   [Full Text] [Related]  

  • 35. Oligonucleotide therapeutics for hematologic disorders.
    Agarwal N; Gewirtz AM
    Biochim Biophys Acta; 1999 Dec; 1489(1):85-96. PubMed ID: 10806999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
    Cho YS; Cho-Chung YS
    Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53.
    Basma H; El-Refaey H; Sgagias MK; Cowan KH; Luo X; Cheng PW
    J Biomed Sci; 2005 Dec; 12(6):999-1011. PubMed ID: 16228292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
    Cho YS; Kim MK; Tan L; Srivastava R; Agrawal S; Cho-Chung YS
    Clin Cancer Res; 2002 Feb; 8(2):607-14. PubMed ID: 11839683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antisense therapy in oncology: present situation].
    Morán González D; Domínguez-Gil Hurlé A
    Farm Hosp; 2005; 29(4):269-82. PubMed ID: 16268744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense oligonucleotides targeting RI alpha subunit of protein kinase A. In vitro and in vivo anti-tumor activity and pharmacokinetics.
    Zhang R; Wang H
    Methods Mol Med; 2003; 75():637-54. PubMed ID: 12407769
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.